Sasha Pagan, MD
General Practice · Kissimmee, FLNPI 1124236773
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 578 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 23.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,320 and has fallen 62.6% since, to $867 in 2025. Among general practice clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 578 payments — averaging $18.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$1K
- GSK$1K
- AbbVie$863
- Lilly USA, LLC$599
- Pfizer$591
- plus $3K from 27 others
What the payments were for
- Food & beverage$10,474100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 122 | $2,446 |
| AstraZeneca | 66 | $1,493 |
| GSK | 96 | $1,432 |
| AbbVie(2 entities) | 56 | $863 |
| Lilly USA, LLC | 42 | $599 |
| Pfizer | 34 | $591 |
| Boehringer Ingelheim | 31 | $489 |
| Bayer | 13 | $364 |
| Abbott | 13 | $266 |
| Johnson & Johnson | 12 | $222 |
| Merck | 14 | $202 |
| Amarin Pharma, Inc. | 10 | $193 |
| Amgen | 10 | $163 |
| Phathom Pharmaceuticals, Inc. | 7 | $155 |
| Daiichi Sankyo Inc. | 7 | $154 |
| Radius Health, Inc. | 7 | $150 |
| Exact Sciences | 5 | $115 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $113 |
| Sanofi-aventis U.S. LLC | 7 | $100 |
| Biohaven Pharmaceuticals, Inc. | 3 | $44 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| Silk Road Medical, Inc. | 1 | $42 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $32 |
| Axsome Therapeutics, Inc. | 1 | $31 |
| Phadia US Inc. | 2 | $29 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Sumitomo Pharma America, Inc. | 1 | $26 |
| Astellas Pharma US Inc | 1 | $22 |
| Corcept Therapeutics | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| Gilead | 1 | $15 |
| Novartis | 1 | $14 |
| Eisai Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$483
- FARXIGA$360
- VRAYLAR$138
- Ozempic$124
- Xultophy 100/3.6$122
How this compares
$10,488 in reported general payments places this provider in the 95th percentile of 6,901 general practice providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 60 | $63,733 |
| OzempicSemaglutide | 50 | $58,854 |
| EliquisApixaban | 44 | $52,829 |
| TrulicityDulaglutide | 22 | $37,273 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $31,060 |
| JardianceEmpagliflozin | 24 | $26,855 |
| FarxigaDapagliflozin Propanediol | 19 | $21,057 |
| JanuviaSitagliptin Phosphate | 13 | $18,576 |
| XareltoRivaroxaban | 15 | $14,792 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $4,718 |
| Atorvastatin Calcium | 440 | $4,650 |
| Losartan Potassium | 388 | $3,958 |
| Rosuvastatin Calcium | 243 | $3,657 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 119 | $2,597 |
| Gabapentin | 185 | $2,489 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $599 | $101,00582 claims |
| Novo NordiskOzempic, Novolog | $2,446 | $60,80163 claims |
| PfizerEliquis | $591 | $52,82944 claims |
| GSKTrelegy Ellipta | $1,432 | $31,06039 claims |
| Boehringer IngelheimJardiance | $489 | $26,85524 claims |
| AstraZenecaFarxiga, Symbicort | $1,493 | $25,77532 claims |
| MerckJanuvia | $202 | $18,57613 claims |
| Johnson & JohnsonXarelto | $222 | $14,79215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,901 general practice providers in Florida.
Other general practice in Kissimmee
- Miguel Melendez MunozKissimmee$25K
- Robert VogelPalm Beach Gardens$1M
- Bruce OuelletteWest Palm Beach$724K
- Caley CasteleinMiami Beach$586K
- Sarah JockinTampa$308K
- Mario RomeroSarasota$275K
- Robert RitterJupiter$233K
- Robert AltharPensacola$231K
- Florencia ZiemkeWest Palm Beach$208K
- Ausberto HidalgoPembroke Pines$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.